Strykr Analysis
BullishStrykr Pulse 74/100. Flows and technicals support a sustained move higher as capital rotates out of tech. Threat Level 2/5.
When the market’s attention is glued to the latest AI drama or the next Bitcoin liquidation cascade, it’s easy to miss the slow, relentless grind of capital into sectors that aren’t sexy but are suddenly essential. This week, health insurers have quietly become the market’s new darlings, as tech’s once-unstoppable rally stalls and investors scramble for cover.
The rotation is real. According to MarketWatch, investors are dumping tech stocks and rotating into health insurers, banks, and retailers. But the real story is in the flows: health insurance ETFs saw their largest weekly inflows since 2021, while tech sector funds posted their first net outflows in over a year. The S&P 500’s tech-heavy XLK is frozen at $180.3, up 0% on the week, while health insurance majors are quietly notching new highs.
What’s driving this shift? It’s not just the usual defensive playbook. This time, the catalyst is a combination of sticky inflation in healthcare costs, new blockbuster obesity drugs (see Boehringer-Zealand’s latest results), and a market that’s suddenly allergic to high-multiple tech names. The result: a defensive gold rush that’s catching a lot of fast-money traders off guard.
Let’s run the numbers. UnitedHealth, Humana, and Elevance are all trading within spitting distance of their 52-week highs. The Health Care Select Sector SPDR Fund (XLV) is up 4% in the last month, while XLK is flat. The flows tell the story: $2.1 billion into health insurance ETFs in the past week, according to Bloomberg, versus $1.7 billion out of tech. That’s not a rotation, that’s a stampede.
The macro backdrop is adding fuel to the fire. With the Fed hinting at more rate hikes after a blowout jobs report, the market is bracing for tighter financial conditions. Tech stocks, already priced for perfection, are suddenly vulnerable. Meanwhile, health insurers are sitting pretty, with pricing power, stable cash flows, and a regulatory environment that looks more favorable by the day.
Don’t underestimate the impact of the new obesity drug data. Boehringer Ingelheim’s latest results show its experimental drug can cut visceral and liver fat while sparing lean mass. That’s a game-changer for insurers, who now have a new tool to manage long-term healthcare costs. The market is starting to price in lower claims ratios and higher margins for the industry’s biggest players.
Cross-asset flows are confirming the story. Treasuries are rallying as risk-off sentiment takes hold, while credit spreads in healthcare are tightening. The VIX is ticking higher, but health insurers are barely flinching. In a market obsessed with volatility, that kind of resilience is worth its weight in gold.
Strykr Watch
Technically, the health insurance sector is breaking out. The XLV is pushing above its 50-day and 200-day moving averages, with RSI at 68, just shy of overbought, but not yet stretched. UnitedHealth is flirting with $570 resistance, while Humana is consolidating above $510. Watch for a decisive close above these levels to confirm the breakout.
Option flows are picking up, with call volume outpacing puts by 2:1 in the major insurers. Implied volatility is still low, suggesting traders are betting on a slow grind higher rather than a melt-up. But don’t sleep on the potential for a squeeze if tech continues to unwind.
The relative strength of health insurers versus tech is at its highest since early 2024. If XLK can’t regain momentum, expect this trend to accelerate. The algos are watching, and so should you.
The risks? A sudden reversal in tech could trigger a violent rotation back out of defensives. But with fund managers still overweight growth, the pain trade is higher for health insurers.
On the opportunity side, look for pullbacks in XLV and the major insurers as entry points. The sector is not cheap, but it’s not priced for perfection either. A breakout above recent highs could trigger another leg up as the rotation trade gathers steam.
Strykr Take
This isn’t just another defensive rotation. Health insurers are quietly becoming the market’s new leadership group as tech stumbles. The flows are real, the breakout is real, and the pain trade is higher. Ignore the slow grind at your own risk.
Sources (5)
Boehringer-Zealand's obesity drug shows promise in cutting visceral, liver fat
Boehringer Ingelheim said on Sunday ​its experimental obesity drug cut visceral and liver fat while minimizing loss of lean mass in ‌a late-stage stud
‘LIFE CHANGING': Wall Street sees MAJOR SHIFT in the ‘experience economy'
‘The Big Money Show' examines why investors are growing increasingly bullish on live entertainment as Americans flock to concerts, sporting events and
Bring Your Own Power, Ireland Tells Tech Titans Hungry for Data Centers
The tiny nation is a test case for countries seeking AI investment without risking outages or higher bills for citizens.
These are the market's new hot stocks as investors flee from tech
Investors are suddenly dumping technology stocks and rotating into other areas — including health insurers, banks and retailers.
Sen. Armstrong Advocates for Energy Infrastructure Expansion
Senator Alan Armstrong recently resigned as the executive chairman of Williams Companies to replace Markwayne Mullin in the Senate. Armstrong joined D